updated ballieu report - target range 25-55c, page-6

I find Stuart Roberts opinion interesting, but only as an opinion.

He does write many many words .. and there is some meaning in there.

On previous reports for other companies & the blog he had been writing -- I felt he doesn't have great handle on probability of success. Those numbers seem made up to allow a specific per-share valuation.

I wonder if there is too long spent talking to the company & doesn't have a bunch of researchers, clinicians, and hospital buyers to refer to. From such external insights you are more likely to get a good sense of the true risks for any biotech.